The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.
Founded in 2006
Over 60 employees
Proprietary alfapump® & DSR technologies
Headquarters in Ghent, Belgium
Manufacturing in Zurich, Switzerland
Listed on Euronext Brussels
Catch-up on our latest news coverage
Learn more about NASH, ascites, diuretic-resistant fluid overload and heart failure.
Watch and learn more about Sequana Medical, our alfapump® & DSR technologies and target disease areas.
Follow Sequana Medical’s blog posts.
Discover more about our business activities in our latest annual report.
Read our latest news and discover upcoming & recent presentations.
Best Technology Award, European Mediscience Awards, June 2023
Best Overall Medical Device Product Award 4th Annual Medtech Breakthrough Awards, May 2020
Highly Commended Accolade within the Medtech of the Year Award 2019 Lifestars Awards, November 2019
Download our company logo and pictures.